Merilyn Sleigh

Dr. Sleigh has over 30 years of experience as a senior executive and non-executive director in Australia's biotechnology sector. Dr Sleigh was, from its foundation, Chief Executive Officer and Managing Director of EvoGenix Limited, a biotech startup company that internationally and listed on the ASX before acquisition by a larger company, resulting in attractive returns for its investors. Dr. Sleigh was formerly Dean of the Faculty of Life Sciences, University of NSW; Director of Research & Development at Australian biotech Peptech Ltd and a research scientist and senior manager with CSIRO. Dr Sleigh has held non-executive director positions with ASX listed companies Clover Corporation, and Tyrian Diagnostics Ltd. as well as with Adalta Ltd and Mimetica Pty Ltd. Other director roles have been with government and not for profit organisations, including the Rural Industries Research and Development Corporation and Relationships Australia. She has acted as an adviser and consultant to companies, government, research institutes and investors on technology commercialisation.

Company and Role

Company
Title
Tenure
Since
BDX
BCAL Diagnostics Limited
  • Non-Executive Director
2yrs, 11mthMar 2021

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
BDX
BCAL Diagnostics Limited
29/09/23325,000N/AN/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
BDX
BCAL Diagnostics Limited
18/09/23
Buy
200,000$0.100$20,000Participation in share purchase plan
BDX
BCAL Diagnostics Limited
02/05/23
Buy
45,000$0.091$4,095On-market trade
BDX
BCAL Diagnostics Limited
01/03/22
Buy
80,000$0.110$8,800On-market trade